Tin-Wing Yen1, Beth Payne2, Ziguang Qu2, Jennifer A Hutcheon3, Tang Lee2, Laura A Magee4, Barry N Walters5, Peter von Dadelszen3. 1. Department of Obstetrics and Gynaecology, University of British Columbia, Vancouver BC. 2. Department of Obstetrics and Gynaecology, University of British Columbia, Vancouver BC; The Child and Family Research Institute Reproduction and Healthy Pregnancy Cluster, University of British Columbia, Vancouver BC. 3. Department of Obstetrics and Gynaecology, University of British Columbia, Vancouver BC; The Child and Family Research Institute Reproduction and Healthy Pregnancy Cluster, University of British Columbia, Vancouver BC; School of Public and Population Health, University of British Columbia, Vancouver BC. 4. Department of Obstetrics and Gynaecology, University of British Columbia, Vancouver BC; The Child and Family Research Institute Reproduction and Healthy Pregnancy Cluster, University of British Columbia, Vancouver BC; Department of Medicine, University of British Columbia, Vancouver BC; School of Public and Population Health, University of British Columbia, Vancouver BC. 5. Department of Medicine, King Edward Memorial Hospital, Subiaco WA, Australia; Department of Obstetrics and Gynaecology, King Edward Memorial Hospital, Subiaco WA, Australia.
Abstract
OBJECTIVES: Preeclampsia is a leading cause of maternal morbidity. The clinical challenge lies in predicting which women with preeclampsia will suffer adverse outcomes and would benefit from treatment, while minimizing potentially harmful interventions. Our aim was to determine the ability of maternal symptoms (i.e., severe nausea or vomiting, headache, visual disturbance, right upper quadrant pain or epigastric pain, abdominal pain or vaginal bleeding, and chest pain or dyspnea) to predict adverse maternal or perinatal outcomes. METHODS: We used data from the PIERS (Pre-eclampsia Integrated Estimate of RiSk) study, a multicentre, prospective cohort study designed to investigate the maternal risks associated with preeclampsia. Relative risks and receiver operating characteristic (ROC) curves were assessed for each preeclampsia symptom and outcome pair. RESULTS: Of 2023 women who underwent assessment, 52% experienced at least one preeclampsia symptom, with 5.2% and 5.3% respectively experiencing an adverse maternal or perinatal outcome. No symptom and outcome pair, in either of the maternal or perinatal groups, achieved an area under the ROC curve value > 0.7, which would be necessary to demonstrate a discriminatory predictive value. CONCLUSION: Maternal symptoms of preeclampsia are not independently valid predictors of maternal adverse outcome. Caution should be used when making clinical decisions on the basis of symptoms alone in the preeclamptic patient.
OBJECTIVES: Preeclampsia is a leading cause of maternal morbidity. The clinical challenge lies in predicting which women with preeclampsia will suffer adverse outcomes and would benefit from treatment, while minimizing potentially harmful interventions. Our aim was to determine the ability of maternal symptoms (i.e., severe nausea or vomiting, headache, visual disturbance, right upper quadrant pain or epigastric pain, abdominal pain or vaginal bleeding, and chest pain or dyspnea) to predict adverse maternal or perinatal outcomes. METHODS: We used data from the PIERS (Pre-eclampsia Integrated Estimate of RiSk) study, a multicentre, prospective cohort study designed to investigate the maternal risks associated with preeclampsia. Relative risks and receiver operating characteristic (ROC) curves were assessed for each preeclampsia symptom and outcome pair. RESULTS: Of 2023 women who underwent assessment, 52% experienced at least one preeclampsia symptom, with 5.2% and 5.3% respectively experiencing an adverse maternal or perinatal outcome. No symptom and outcome pair, in either of the maternal or perinatal groups, achieved an area under the ROC curve value > 0.7, which would be necessary to demonstrate a discriminatory predictive value. CONCLUSION: Maternal symptoms of preeclampsia are not independently valid predictors of maternal adverse outcome. Caution should be used when making clinical decisions on the basis of symptoms alone in the preeclamptic patient.
Authors: Laura A Magee; Edgardo Abalos; Peter von Dadelszen; Baha Sibai; Tom Easterling; Steve Walkinshaw Journal: Br J Clin Pharmacol Date: 2011-09 Impact factor: 4.335
Authors: Asif R Khowaja; Craig Mitton; Stirling Bryan; Laura A Magee; Zulfiqar A Bhutta; Peter von Dadelszen Journal: Implement Sci Date: 2015-05-26 Impact factor: 7.327
Authors: Asif Raza Khowaja; Rahat Najam Qureshi; Diane Sawchuck; Olufemi T Oladapo; Olalekan O Adetoro; Elizabeth A Orenuga; Mrutyunjaya Bellad; Ashalata Mallapur; Umesh Charantimath; Esperança Sevene; Khátia Munguambe; Helena Edith Boene; Marianne Vidler; Zulfiqar A Bhutta; Peter von Dadelszen Journal: Reprod Health Date: 2016-06-08 Impact factor: 3.223
Authors: Peter von Dadelszen; Meriel Flint-O'Kane; Lucilla Poston; Rachel Craik; Donna Russell; Rachel M Tribe; Umberto d'Alessandro; Anna Roca; Hawanatu Jah; Marleen Temmerman; Angela Koech Etyang; Esperança Sevene; Paulo Chin; Joy E Lawn; Hannah Blencowe; Jane Sandall; Tatiana T Salisbury; Benjamin Barratt; Andrew H Shennan; Prestige Tatenda Makanga; Laura A Magee Journal: Reprod Health Date: 2020-04-30 Impact factor: 3.223